Sphingosine kinase (SK) catalyzes the formation of sphingosine 1-phosphate (S1P), a lipid messenger that plays an important role in a variety of mammalian cell processes, including inhibition of apoptosis and stimulation of cell proliferation. Basal levels of S1P in cells are generally low but can increase rapidly when cells are exposed to various agonists through rapid and transient activation of SK activity. To date, elucidation of the exact signaling pathways affected by these elevated S1P levels has relied on the use of SK inhibitors that are known to have direct effects on other enzymes in the cell. Furthermore, these inhibitors block basal SK activity, which is thought to have a housekeeping function in the cell. To produce a specific inhibitor of SK activation we sought to generate a catalytically inactive, dominant-negative SK. This was accomplished by site-directed mutagenesis of Gly 82 to Asp of the human SK, a residue identified through sequence similarity to the putative catalytic domain of diacylglycerol kinase. This mutant had no detectable SK activity when expressed at high levels in HEK293T cells. Activation of endogenous SK activity by tumor necrosis factor-␣ (TNF␣), interleukin-1␤, and phorbol esters in HEK293T cells was blocked by expression of this inactive sphingosine kinase (hSK G82D ). Basal SK activity was unaffected by expression of hSK G82D . Expression of hSK G82D had no effect on TNF␣-induced activation of protein kinase C and sphingomyelinase activities. Thus, hSK G82D acts as a specific dominant-negative SK to block SK activation. This discovery provides a powerful tool for the elucidation of the exact signaling pathways affected by elevated S1P levels following SK activation. To this end we have employed the dominant-negative SK to demonstrate that TNF␣ activation of extracellular signal-regulated kinases 1 and 2 (ERK1,2) is dependent on SK activation.
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has been implicated in the regulation of a variety of important mammalian cell processes, including proliferation, differentiation, and apoptosis (1) (2) (3) . Specifically, some of the diverse signaling roles attributed to elevated cellular S1P levels include prevention of ceramide-induced apoptosis (4, 5) , calcium mobilization (6) , stimulation of DNA binding activity of the transcription factor activator protein-1 (7), activation of mitogenactivated protein kinase pathways (8, 9) , activation of phospholipase D (10) , and stimulation of adhesion molecule expression (9) .
Cellular levels of S1P are largely mediated by its formation from sphingosine by the activity of sphingosine kinase (SK) and to a lesser extent by its degradation by S1P lyase (11) and S1P phosphatase (12, 13) activities. Cultured mammalian cells, in the absence of stimulating factors, have basal SK activity; however numerous studies have shown that this activity can be rapidly increased by certain cell agonists. Depending on cell type, some of the diverse agonists that stimulate SK activity include tumor necrosis factor-␣ (TNF␣) (4, 9) , platelet-derived growth factor (14) , nerve growth factor (15, 16) , n-formyl-methionyl-leucyl-phenylalanine (17) , muscarinic acetylcholine agonists (18) , serum (14) , phorbol esters (19, 20) , and engagement of the Fc⑀RI (21) and Fc␥RI (22) antigen receptors. Stimulation of SK activity by these agonists results in rapid and transient increases in cellular S1P, the basal levels of which are generally low (2, 14) , triggering the downstream pathways described earlier.
Although cell agonists stimulate SK activity, there is considerable basal activity found in unstimulated cells. We have previously suggested this may represent dual roles for SK in the cell (23) . Basal activity is likely to be required for a "housekeeping" function as part of the sphingomyelin degradative pathway (3, 24) clearing the cell of sphingosine and ceramide, two molecules with apparent pro-apoptotic functions (3, 25) . In contrast, the higher levels of SK activity seen upon cell stimulation with various cell agonists appear to confer cell signaling roles for this enzyme through the production of S1P (1, 2) .
To date, studying the roles of agonist-induced SK activation and the resultant elevated S1P levels in cell signaling has relied upon the use of SK inhibitors to decrease S1P formation in response to agonist stimulation of cells, as well as the addi-* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Supported by a G. Dowling Medical Research Associateship from the University of Adelaide.
ʈ Supported by a Fellowship from the National Heart Foundation of Australia. ** Supported by grants from the National Health and Medical Research Council of Australia. ‡ ‡ Supported by a H. M. Lloyd Senior Research Fellowship in Oncology from the University of Adelaide.
§ § To whom correspondence should be addressed. Tel.: 618-8222-3472; Fax: 618-8232-4092; E-mail: brian.wattenberg@imvs.sa.gov.au. 1 The abbreviations used are: S1P, sphingosine 1-phosphate; SK, sphingosine kinase; TNF␣, tumor necrosis factor-␣; hSK, human SK1; hSK G82D , hSK with Gly 82 3 Asp mutation; hSK WT , wild-type hSK; dnSK, dominant-negative SK; ERK1,2, extracellular signal-regulated kinases 1 and 2; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; IL-1, interleukin-1␤; HA, hemagglutinin; DGK, diacylglycerol kinase.
tion of endogenous S1P in these conditions to resurrect S1P-mediated signaling. This system, although providing useful insights into the roles of SK activation and S1P, is not ideal. Three main inhibitors of sphingosine kinase are known, N,Ndimethylsphingosine, N,N,N-trimethylsphingosine, and DLthreo-dihydrosphingosine (23) . Although these inhibitors have been used extensively in studies examining the role of S1P and SK, unfortunately they do not show absolute specificity to SK. Instead, they appear to have secondary effects on the cell, including inhibition of protein kinase C (PKC) (26, 27) , activation of sphingosine-dependent protein kinases (28), 3-phosphoinositide-dependent kinase 1 (29) , and casein kinase II (30) , among numerous other effects on the cell (3). Additionally, their use inhibits basal (housekeeping) SK activity in cells, inevitably leading to increases in cellular sphingosine and ceramide levels and resulting in modulation of signaling pathways affected by these molecules (3, 25) . To add further complexity, the addition of endogenous S1P to cells not only resurrects intracellular signaling functions of S1P but also triggers numerous other pathways leading from the recently identified EDG family of G protein-coupled S1P-specific cell surface receptors, of which four isoforms are known (31) (32) (33) (34) . This has made interpretation of the exact roles of S1P in cell signaling difficult.
In this study we have overcome the problems associated with the use of these SK inhibitors and addition of exogenous S1P by the development of a dominant-negative SK that specifically blocks SK activation, while leaving the relatively high basal SK activity unaltered. Cell Culture and Transfection-Human embryonic kidney cells (HEK293T, ATCC CRL-1573) were cultured on Dulbecco's modified Eagle's medium (CSL Biosciences, Parkville, Australia) containing 10% fetal calf serum, 2 mM glutamine, 0.2% (w/v) sodium bicarbonate, 1.2 mg/ml penicillin, and 1.6 mg/ml gentamycin. Transfections were performed using the calcium phosphate precipitation method (35) . High transfection efficiency (Ͼ90%) of these cells was confirmed using immunofluorescence with the M2 anti-FLAG antibody (Sigma) and fluorescein-conjugated anti-mouse Ig (Selinus/Amrad, Melbourne, Australia). Cells were harvested and lysed by sonication (2 watts for 30 s at 4°C) in lysis buffer containing 50 mM Tris/HCl (pH 7.4), 10% glycerol, 0.05% Triton X-100, 150 mM NaCl, 1 mM dithiothreitol, 2 mM Na 3 VO 4 , 10 mM NaF, 1 mM EDTA, and protease inhibitors (Complete TM ; Roche Molecular Biochemicals). Protein concentrations in cell homogenates were determined with either the Coomassie Brilliant Blue (Sigma) or bicinchoninic acid (Pierce) reagents using bovine serum albumin as standard.
EXPERIMENTAL PROCEDURES

Materials-D-erythro-Sphingosine
Cloning of Human Sphingosine Kinase-Human SK1 (hSK) cDNA (GenBank TM accession number AF200328) was FLAG epitope-tagged at the 3Ј end and subcloned into pcDNA3 vector, as described previously (23) . For coexpression experiments hSK cDNA was hemagglutinin (HA) epitope-tagged at the 3Ј end by Pfu DNA polymerase chain reaction with oligonucleotide primers 5Ј-TTGAACCATTATGCTGGCTATGA-3Ј and 5Ј-TATCTAGAAGCTTAGGCGTAGTCTGGCACGTCGTATGGGT-ATAAGGGCTCTTCTGGCGGT-3Ј. The polymerase chain reaction product was digested with ApaI-XbaI, and the resultant HA-tagged hSK cassette was subcloned to generate pGEM4Z-hSK-HA. The HAtagged hSK cDNA was then cloned into pcDNA3 by digestion with EcoRI-XbaI. Sequencing verified the integrity of the cDNA sequence.
Construction and Expression of hSK
G82D
-The FLAG-tagged hSK cDNA (23) was cloned into pALTER (Promega Inc., Madison, WI) sitedirected mutagenesis vector. Single-stranded DNA was prepared and used as a template for oligonucleotide-directed mutagenesis as detailed in the manufacturer's protocol. The mutagenic oligonucleotide (5Ј-CT-GGAGACGATCTGATGCAC-3Ј) was designed to generate the hSK G82D mutant by substitution of the Gly 82 to Asp. The mutant was sequenced to verify incorporation of the desired modification. The hSK G82D mutant cDNA was then subcloned into pcDNA3 (Invitrogen Corp., San Diego, CA) for transient transfection into HEK293T cells.
Enzyme Assays-SK activity was determined using D-erythro-sphingosine and [␥-
32 P]ATP as substrates, as described previously (23) . Neutral sphingomyelinase activity was determined using [choline-methyl- 14 C]sphingomyelin as substrate, essentially as described previously (36) . Briefly, whole cell lysates, prepared as described above, were added to an equal volume of 100 mM Tris/HCl buffer (pH 7.4) containing 0.2% Triton X-100, 10 mM MgCl 2 , and [choline-methyl- 14 C]sphingomyelin (50,000 cpm/assay) and incubated at 37°C for 60 min. Radioactive phosphorylcholine produced was then extracted with chloroform/methanol (2:1, v/v) and quantified in the aqueous phase by scintillation counting. The measurement of PKC activity in situ was performed as described previously (37) . Briefly, cells were seeded in 24-well plates and maintained in culture medium until 70 -80% confluent. After the indicated treatments, the cells were washed with Dulbecco's modified Eagle's medium and placed in 60 l of buffered salt solution (137 mM NaCl, 5.4 mM KCl, 0.3 mM Na 2 HPO 4 , 0.4 mM KH 2 PO 4 , 5.5 mM glucose, and 20 mM HEPES) supplemented with 50 g/ml digitonin, 10 mM MgCl 2 , 25 mM ␤-glycerophosphate, and 10 M [␥-
32 P]ATP (5000 cpm/ pmol). A PKC-specific peptide substrate (RKRTLRRL) was then added (to 200 M) in the presence of 5 mM EGTA and 2.5 mM CaCl 2 . After a 10-min incubation at 30°C, the kinase reaction was terminated by the addition of 20 l of 25% (w/v) trichloroacetic acid. Aliquots (65 l) of the acidified reaction mixtures were spotted on phosphocellulose papers (Whatman P-81) and washed three times with 75 mM phosphoric acid and once with 75 mM sodium phosphate buffer, pH 7.5. The PKC-dependent phosphorylated peptide substrate bound to the filter was quantified by scintillation counting.
Measurement of Cellular S1P-Relative cellular S1P levels following TNF␣ treatment were determined after a 4-h preincubation of cells in serum and phosphate-free medium containing 100 Ci/ml [ 32 P]orthophosphate. Cells were washed with phosphate-buffered saline and harvested and lysed in 300 l of 50 mM Tris/HCl buffer (pH 7.4) containing 1% Triton X-100, 2 mM Na 3 VO 4 , 10 mM NaF, and protease inhibitors (Complete TM ; Roche Molecular Biochemicals). Lipids were then extracted with 1.5 ml of chloroform/methanol,1 M NaCl (2:2:1, v/v) containing 50 l of 3 M NaOH. Under these alkaline conditions S1P is water-soluble and partitions to the aqueous phase. The aqueous phase was then collected, acidified by the addition of 25 l of concentrated HCl, and extracted with 1.2 ml of chloroform/methanol/concentrated HCl (100:100:1, v/v) to partition S1P to the organic phase. [ 32 P]S1P in the organic phase was then isolated by TLC on Silica Gel 60 with 1-butanol/ethanol/acetic acid/water (8:2:1:2, v/v) and quantitated by PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
Western Blotting-SDS-polyacrylamide gel electrophoresis was performed on cell lysates according to the method of Laemmli (38) using 12% acrylamide gels. Proteins were blotted to nitrocellulose, and the membranes were blocked overnight at 4°C in PBS containing 5% skim milk and 0.1% Triton X-100. SK expression levels were analyzed with either a monoclonal anti-HA antibody (12CA5) or M2 anti-FLAG antibody (Sigma). ERK activation in response to agonists was followed in cells serum-starved for 4 h using anti-ERK1,2 (Zymed Laboratories Inc., San Francisco, CA) and anti-phospho-ERK1,2 (Promega, Madison, WI) antibodies. Immunocomplexes were detected after conjugation to either horseradish peroxidase-conjugated anti-mouse (Pierce) or antirabbit (Selinus/Amrad, Melbourne, Australia) IgG using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech).
RESULTS AND DISCUSSION
Production of a Catalytically Inactive Sphingosine Kinase by
Site-directed Mutagenesis-We have recently cloned and characterized hSK (23) . A search of the hSK amino acid sequence for signaling domains using the SMART search tool (39, 40) revealed similarity in residues 16 -153 to the putative catalytic domain of diacylglycerol kinases (DGK). hSK showed an overall 36% identity to the consensus sequence of the DGK catalytic domain family and possessed 17 of the 24 very highly conserved amino acids of this domain (Fig. 1) . One region of the hSK sequence showing highest similarity corresponded to the proposed ATP binding site of the DGK catalytic domain (47) . This region in DGK displays some resemblance to the glycine-rich loop within the ATP binding site of many protein kinases (48, 49) but is more divergent in hSK. A glycine residue in this region is known to be essential for DGK catalytic activity because mutation of this residue to aspartate ablates activity in all DGKs examined (41, 47, 50) . Therefore, in an attempt to produce a catalytically inactive hSK, we also mutated the corresponding glycine (Gly 82 ) to aspartate in hSK. We then expressed this hSK G82D , as well as the wild-type hSK (hSK WT ), in HEK293T cells and assayed the cell lysates for SK activity (Fig.  2) . As previously reported (23), expression of hSK WT produces a substantial (approximately 2000-fold) increase in SK activity over the endogenous levels. In contrast, similar expression of hSK G82D produced no detectable increase in SK activity. This demonstrated that, as for DGKs, the Gly 82 to Asp mutation ablated catalytic activity in hSK and due to its similarity to the glycine-rich loop of protein kinases, may suggest that this region of the enzyme is involved in ATP binding.
Expression of hSK G82D Blocks Activation of Endogenous SK Activity by Various Cell Agonists-Numerous previous studies
have shown that expression of catalytically inactive enzymes can result in dominant-negative function by preventing activation of the wild-type endogenous enzyme (e.g. Refs. [51] [52] [53] ). Therefore, we tested whether hSK G82D could act in a similar manner to block endogenous SK activation by various cell agonists in HEK293T cells. Cells were transiently transfected with either pcDNA3-hSK G82D or empty vector, and the SK activity was determined in response to treatment with TNF␣, IL-1, and PMA. As observed previously (4, 9, 20) , TNF␣ and PMA stimulated endogenous SK activity approximately 2-fold in the empty vector transfected HEK293T cells (Fig. 3) . Similar stimulation of SK activity was also observed in these cells with IL-1 (Fig. 3) . However, strikingly, in cells expressing hSK G82D no activation of endogenous SK activity was observed in response to either TNF␣ or IL-1, whereas PMA treatment resulted in only a small increase in SK activity (Fig. 3) . Basal levels of SK activity were maintained in both unstimulated and stimulated cells in the presence of hSK G82D . Further examination of the time course of TNF␣ stimulation (Fig. 4) showed that expression of hSK G82D blocked activation of SK activity even after an extended period of stimulation. SK activity was maintained at unstimulated levels, demonstrating that hSK G82D blocks activation but not basal SK activity. Cellular S1P levels were also measured in parallel with SK activity. As predicted, cells expressing hSK G82D showed no transient increase in S1P levels in response to TNF␣, while basal S1P levels were maintained. It is especially notable that hSK G82D does not reduce S1P levels in either unstimulated or stimulated cells. This demonstrates that, in the intact cell, hSK G82D does not block S1P formation by sequestering substrate, which would reduce both basal and stimulated S1P levels. This effect would be missed in in vitro SK assays where substrate is in excess but theoretically could be important in cells where substrate could be limiting. Also of note was that the time course for increased S1P levels occurs at a slightly earlier stage than that for SK activity. This may be due to increased S1P lyase (11) or S1P phosphatase (12) activity, clearing the cell of S1P, although currently nothing is known regarding the regulation of these enzymes.
Combined, these data indicate that hSK G82D indeed acts as a dominant-negative SK (dnSK) in ablating activation of endogenous SK activity.
Specificity of hSK G82D Dominant-Negative Function-To establish the specificity of hSK G82D as a dominant-negative for SK activation, we examined other pathways stimulated by TNF␣ that should not be affected by hSK G82D . Previous studies have shown that both sphingomyelinase (36, 54) and PKC (37, 55) activity are stimulated by TNF␣. Therefore, HEK293T cells were transiently transfected with either pcDNA3-hSK G82D or empty vector, and the sphingomyelinase and PKC activity was determined in response to treatment with TNF␣. Activation of both enzymes by TNF␣ was unaffected by the presence of hSK G82D (Fig. 5 ). This illustrates that hSK G82D is a specific dominant-negative for SK activation by TNF␣, blocking that activation and not other TNF␣ signaling pathways. hSK G82D Decreases TNF␣-induced Activation of Overexpressed hSK WT -We have previously shown that TNF␣ can rapidly induce an approximate 2-fold increase in the already high levels of SK activity resulting from the overexpression of hSK WT in HEK293T cells in a parallel manner to the activation . HEK293T cells transfected with either pcDNA3-hSK G82D (q) or empty pcDNA3 vector (E) were treated with 1 ng/ml TNF␣. Cells were harvested at various times over 45 min of TNF␣ treatment (1 ng/ml), and the cell lysates were assayed for SK activity (A) and S1P levels (B). All values shown are relative to untreated HEK293T cells transfected with empty pcDNA3 vector.
FIG. 5. Expression of hSK
G82D in HEK293T cells does not affect activation of sphingomyelinase activity by TNF␣ or PKC activity by TNF␣ or PMA. HEK293T cells were transfected with either pcDNA3-hSK G82D (q and filled bars) or empty pcDNA3 vector (E and open bars). A, cells were harvested at various times over 45 min of TNF␣ treatment (1 ng/ml), and the cell lysates were assayed for sphingomyelinase activity. SK activity from these lysates is shown in Fig. 4 . All values shown are relative to untreated HEK293T cells transfected with empty pcDNA3 vector. B, cells were treated with 1 ng/ml TNF␣ for 10 min or 100 ng/ml PMA for 30 min and assayed for PKC activity.
of endogenous SK activity (23) . Similar results were also recently reported with platelet-derived growth factor stimulation of NIH 3T3 fibroblasts expressing a murine SK (56) . Therefore, we tested the ability of hSK G82D to block the activation of these high levels of hSK WT (2000-fold overexpression) by following TNF␣-induced stimulation of SK activity in HEK293T cells coexpressing hSK WT and hSK G82D . To confirm similar levels of expression, the two SK forms were constructed with different epitope tags. The presence of equimolar levels of hSK G82D blocked TNF␣ stimulation of hSK WT activity by approximately 50% (Fig. 6) . The high basal SK activity in unstimulated cells was unaffected by hSK G82D . These data suggest that the mechanism whereby hSK G82D acts as a dominant-negative is through direct competition with SK WT for the, as yet unknown, upstream activator of SK. This proposed mechanism is further supported by the observation that, in untreated cells, hSK G82D does not affect basal endogenous (Fig. 3) or overexpressed SK activity (Fig. 6) . Similarly, cell extracts containing high levels of hSK G82D did not inhibit the activity of purified human SK in vitro (data not shown), demonstrating that hSK G82D blocks SK activation and not SK activity itself. By inference, these data also support our previous studies (23) suggesting that hSK is a constitutively active enzyme that does not require activation for basal activity.
Expression of hSK G82D Prevents TNF␣-induced ERK Activation-Having established that hSK G82D acts as a specific dominant-negative to ablate activation of endogenous SK by a range of cell agonists, we examined its effect on a pathway proposed to be mediated by S1P and SK activation. Previous studies had shown that activation of extracellular signal-regulated kinase 1 and 2 (ERK1,2) activity by TNF␣ appears to be mediated by SK activation through transient increases in cellular S1P levels (9) . Thus, we examined the effect of hSK G82D expression on ERK1,2 activation by TNF␣. HEK293T cells were transiently transfected with either pcDNA3-hSK G82D or empty vector, and the activation of ERK was determined in response to treatment with TNF␣ and PMA through Western blotting with an anti-phospho-ERK1,2 antibody. Treatment of HEK293T cells transfected with empty vector with TNF␣ rapidly stimulated activation of ERK1,2 (Fig. 7) . In marked contrast, activation of ERK1,2 by TNF␣ is blocked in HEK293T cells expressing hSK G82D (Fig. 7) . PMA-induced activation of ERK1,2, however, remains unaffected demonstrating that expression of hSK G82D does not inherently affect ERK1,2 activation. The activation of ERK1,2 by PMA in the presence of hSK G82D is not surprising because it is known that ERK activation can be achieved by several pathways independent of SK and S1P (57, 58) . Therefore, these data provide, for the first time, unequivocal evidence for the requirement of SK activation and raised cellular S1P levels in TNF␣-induced ERK1,2 activation without resorting to the use of chemical inhibitors of questionable specificity. At present the mechanism of this S1P-mediated ERK1,2 activation is unclear. Previous studies have shown that exogenous S1P can activate the mitogen-activated protein kinase pathway via the EDG family of G protein-coupled S1P cell surface receptors (31, 32, 59, 60) . Therefore, it is tempting to speculate that the increased intracellular S1P levels resulting from activation of SK activity lead to secretion of S1P and subsequent engagement of S1P cell surface receptors and activation of ERK1,2. However, previous studies have failed to detect S1P in media from HEK293T and NIH 3T3 cells producing high cellular S1P levels through overexpression of murine SK (56) . This instead suggests that S1P may activate ERK1,2 via an intracellular mechanism, as has been suggested for other S1P-mediated pathways (61) .
Conclusions and Implications of this Study-This study has described the construction and characterization of a dnSK that selectively blocks activation of SK by various cell agonists. Although the dnSK is based on human SK1, which we (23) and others (62, 63) have recently cloned, it should be noted that a second human SK isoform (hSK2) has also been identified recently (44) . At present the relative abundance of hSK2 compared with hSK is not known, nor is it known if the activity of hSK2 is activated by cell agonists. However, the data from our current study suggest that hSK2 is either in relatively low abundance in HEK293T cells or is not activated, or its activation is also blocked by the dnSK.
The mechanism of action of the dnSK appears to be through competition for the, as yet unknown, SK activating molecule. The relatively high basal SK activity is unaffected by expres- G82D or empty pcDNA3 vector were treated with 1 ng/ml TNF␣ for 10 min or 100 ng/ml PMA for 30 min. Cells were harvested, and the cell lysates were analyzed by Western blotting with anti-FLAG, anti-ERK1,2, and anti-phospho-ERK1,2 antibodies. sion of the dnSK. This is an important observation supporting mounting evidence that SK has dual roles in the cell. Basal SK activity is likely to be involved in sphingomyelin turnover, assisting in clearing the cell of sphingosine and ceramide, two molecules with apparent pro-apoptotic functions (3, 25) . In contrast, the activated SK activity seen upon cell stimulation with various cell agonists appears to confer a cell signaling role for this enzyme through the production of elevated S1P levels (1, 2). It is not yet clear whether the stimulated production of S1P confers a signaling role solely by raising S1P levels above a signaling threshold or whether the stimulated formation is localized to specialized sites active for signaling. The dnSK does not affect the housekeeping role of basal SK activity, thus overcoming any associated problems with accumulation of sphingosine and ceramide in the cell, as occurs with N,Ndimethylsphingosine treatment of cells. In contrast, by blocking SK activation the dnSK ablates SK-mediated cell signaling. Thus, the dnSK is a unique and powerful tool for the elucidation of the role of SK activation and the exact downstream targets of the resultant elevated cellular S1P levels.
